ADMA Stock Analysis: ADMA Biologics | NASDAQ

Biotechnology | NASDAQ, USA | Market Cap: 2.267m USD | 12M Return: -28.1% | US0008991046 | Charts, Fundamentals & Technical Analysis

Immune Globulin, Hepatitis Antibodies, Pneumonia Therapeutics, Plasma Collection
Total Rating 52
Safety 89
Buy Signal -0.84
Biotechnology
Industry Rotation: -21.7
Market Cap: 2.27B
Avg Turnover: 27.8M
Risk 3d forecast
Volatility53.1%
VaR 5th Pctl8.50%
VaR vs Median-2.64%
Reward TTM
Sharpe Ratio-0.49
Rel. Str. IBD22
Rel. Str. Peer Group27.3
Character TTM
Beta0.326
Beta Downside0.044
Hurst Exponent0.609
Drawdowns 3y
Max DD68.99%
CAGR/Max DD0.65
CAGR/Mean DD1.88
EPS (Earnings per Share) EPS (Earnings per Share) of ADMA over the last years for every Quarter: "2021-09": -0.13, "2021-12": -0.09, "2022-03": -0.09, "2022-06": -0.07, "2022-09": -0.08, "2022-12": -0.06, "2023-03": -0.03, "2023-06": -0.02, "2023-09": 0.01, "2023-12": 0.04, "2024-03": 0.08, "2024-06": 0.13, "2024-09": 0.15, "2024-12": 0.136, "2025-03": 0.11, "2025-06": 0.14, "2025-09": 0.16, "2025-12": 0.2157, "2026-03": 0.17, "2026-06": 0.16,
Last SUE: 0.00
Qual. Beats: 0
Revenue Revenue of ADMA over the last years for every Quarter: 2021-09: 20.68055, 2021-12: 26.382867, 2022-03: 29.103093, 2022-06: 33.905007, 2022-09: 41.090137, 2022-12: 49.981455, 2023-03: 56.914, 2023-06: 60.123, 2023-09: 67.275, 2023-12: 73.903677, 2024-03: 81.875, 2024-06: 107.191, 2024-09: 119.839, 2024-12: 117.549, 2025-03: 114.802, 2025-06: 121.984, 2025-09: 134.224, 2025-12: 139.163, 2026-03: 114.493, 2026-06: 124.395,
Rev. CAGR: 35.13%
Rev. Trend: 94.8%
Last SUE: -0.09
Qual. Beats: 0

Warnings

Below Sma 200d

Tailwinds

No distinct edge detected

Seasonality 11.7 years of data

Jan +3.4% 15
Feb -4.6% 9
Mar +7.5% 19
Apr +3.2% 5
May +4.5% 8
Jun -5.8% 30
Jul +3.0% 52
Aug -5.6% 5
Sep -5.0% 31
Oct -6.1% 12
Nov +9.6% 51
Dec +0.5% 2

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.

Description: ADMA ADMA Biologics

ADMA Biologics, Inc. is a vertically integrated biopharmaceutical company that develops, manufactures, and markets specialty plasma-derived biologics targeting immune deficiencies and infectious diseases. Its operations span two segments: ADMA BioManufacturing and Plasma Collection Centers, reflecting a model that controls the supply chain from raw plasma sourcing through finished product distribution. The companys marketed portfolio includes BIVIGAM and ASCENIV, both intravenous immune globulin (IVIG) products for primary humoral immunodeficiency, as well as Nabi-HB, a polyclonal antibody for Hepatitis B exposure. ADMA also maintains a pipeline focused on immunoglobulin-based treatments, including candidates targeting S. pneumoniae infection, and operates its own plasma collection facilities to supply its manufacturing operations. Products are sold through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. The plasma-derived biologics sector is characterized by heavy reliance on limited human plasma supplies, long manufacturing lead times, and regulatory oversight by bodies such as the FDA. ADMA Biologics was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

Headlines to Watch Out For
  • ASCENIV and BIVIGAM IVIG sales accelerate revenue growth
  • Plasma collection expansion lifts gross margins through vertical integration
  • FDA approvals and pipeline progression remain key catalysts
Piotroski VR-10 (Strict) 6.0
Net Income: 169.0m TTM > 0 and > 6% of Revenue
FCF/TA: 0.17 > 0.02 and ΔFCF/TA 5.24 > 1.0
NWC/Revenue: 88.32% < 20% (prev 68.46%; Δ 19.86% < -1%)
CFO/TA 0.20 > 3% & CFO 136.7m > Net Income 169.0m
Net Debt (75.1m) to EBITDA (234.8m): 0.32 < 3
Current Ratio: 6.97 > 1.5 & < 3
Outstanding Shares: last quarter (230.3m) vs 12m ago -7.35% < -2%
Gross Margin: 64.71% > 18% (prev 53.00%; Δ 11.70% > 0.5%)
Asset Turnover: 82.45% > 50% (prev 84.92%; Δ -2.47% > 0%)
Interest Coverage Ratio: 25.53 > 6 (EBIT TTM 225.3m / Interest Expense TTM 8.82m)
Altman Z'' 7.95
A: 0.66 (Total Current Assets 528.2m - Total Current Liabilities 75.8m) / Total Assets 684.2m
B: -0.11 (Retained Earnings -78.5m / Total Assets 684.2m)
C: 0.36 (EBIT TTM 225.3m / Avg Total Assets 621.3m)
D: 1.48 (Book Value of Equity 408.2m / Total Liabilities 276.0m)
Altman-Z'' = 7.95 = AAA
Beneish M -3.15
DSRI: 1.17 (Receivables 138.2m/109.7m, Revenue 512.3m/474.2m)
GMI: 0.82 (GM 53.00% / 64.71%)
AQI: 0.74 (AQ_t 0.12 / AQ_t-1 0.17)
SGI: 1.08 (Revenue 512.3m / 474.2m)
TATA: 0.05 (NI 169.0m - CFO 136.7m) / TA 684.2m)
Beneish M = -3.15 (Cap -4..+1) = AA
What is the price of ADMA shares?

As of October 06, 2026, the stock is trading at USD 10.11 with a total of 3,512,188 shares traded. Over the past week, the price has changed by -0.10%, over one month by +5.97%, over three months by +10.37% and over the past year by -28.14%.

Current recommended Stop Loss: 9.40 (which is 7% or 1.8 ATR below the current price).

Is ADMA a buy, sell or hold?

ADMA Biologics has received a consensus analysts rating of 4.33. Therefore, it is recommended to buy ADMA.

  • StrongBuy: 2
  • Buy: 0
  • Hold: 1
  • Sell: 0
  • StrongSell: 0

What are the forecasts/targets for the ADMA price?
Analysts Target Price 17 68.2%
ADMA Biologics (ADMA) - Fundamental Data Overview as of 30 September 2026
Market Cap USD = 2.27b (2.27b USD * 1.0 USD.USD)
P/E Trailing = 14.4571
P/E Forward = 9.7847
P/S = 4.4248
P/B = 5.3169
Revenue TTM = 512.3m USD
EBIT TTM = 225.3m USD
EBITDA TTM = 234.8m USD
Long Term Debt = 192.8m USD (from longTermDebt, last quarter)
Short Term Debt = 4.93m USD (from shortTermDebt, last quarter)
Debt = 211.1m USD (from shortLongTermDebtTotal, last quarter) + Leases 7.25m
Net Debt = 75.1m USD (calculated: Debt 211.1m - CCE 136.0m)
Enterprise Value = 2.34b USD (2.27b + Debt 211.1m - CCE 136.0m)
Interest Coverage Ratio = 25.53 (Ebit TTM 225.3m / Interest Expense TTM 8.82m)
EV/FCF = 20.11x (Enterprise Value 2.34b / FCF TTM 116.5m)
FCF Yield = 4.97% (FCF TTM 116.5m / Enterprise Value 2.34b)
FCF Margin = 22.74% (FCF TTM 116.5m / Revenue TTM 512.3m)
Net Margin = 32.98% (Net Income TTM 169.0m / Revenue TTM 512.3m)
Gross Margin = 64.71% ((Revenue TTM 512.3m - Cost of Revenue TTM 180.8m) / Revenue TTM)
Gross Margin QoQ = 69.36% (prev 70.53%)
Tobins Q-Ratio = 3.42 (Enterprise Value 2.34b / Total Assets 684.2m)
Interest Expense / Debt = 4.18% (Interest Expense 8.82m / Debt 211.1m)
Taxrate = 21.95% (47.5m / 216.5m)
NOPAT = 175.8m (EBIT 225.3m * (1 - 21.95%))
Current Ratio = 6.97 (Total Current Assets 528.2m / Total Current Liabilities 75.8m)
Debt / Equity = 0.52 (Debt 211.1m / totalStockholderEquity, last quarter 408.2m)
Debt / EBITDA = 0.32 (Net Debt 75.1m / EBITDA 234.8m)
Debt / FCF = 0.64 (Net Debt 75.1m / FCF TTM 116.5m)
Total Stockholder Equity = 426.8m (last 4 quarters mean from totalStockholderEquity)
RoA = 27.19% (Net Income 169.0m / Total Assets 684.2m)
RoE = 39.59% (Net Income TTM 169.0m / Total Stockholder Equity 426.8m)
RoCE = 36.36% (EBIT 225.3m / Capital Employed (Equity 426.8m + L.T.Debt 192.8m))
RoIC = 29.92% (NOPAT 175.8m / Invested Capital 587.8m)
WACC = 6.80% (E(2.27b)/V(2.48b) * Re(7.13%) + D(211.1m)/V(2.48b) * Rd(4.18%) * (1-Tc(0.22)))
Discount Rate = 7.13% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -25.72 | Cagr: -1.15%
[DCF] Terminal Value 77.97% ; FCFF base≈96.2m ; Y1≈110.3m ; Y5≈162.3m
[DCF] Fair Price = 10.57 (EV 2.44b - Net Debt 75.1m = Equity 2.37b / Shares 224.0m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.0 | # QB: 0
Revenue Correlation: 94.76 | Revenue CAGR: 35.13% | SUE: -0.09 | # QB: 0
EPS current Quarter (2026-09-30): EPS=0.20 | Chg30d=-4.84% | Revisions=-50% | Analysts=3
EPS current Year (2026-12-31): EPS=0.80 | Chg30d=+0.00% | Revisions=-50% | GrowthEPS=+21.3% | GrowthRev=+4.9%
EPS next Year (2027-12-31): EPS=0.94 | Chg30d=-3.99% | Revisions=-50% | GrowthEPS=+18.4% | GrowthRev=+17.6%
[Analyst] Revisions Ratio: -75% (up=0, down=9)